A Phase 3 interventional study of Atorvastatin and Ezetimibe in Hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Completed at 70 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-23.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.
Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 14th largest by enrollment, is one of 12 that started in 2012, is one of 20 in phase 3, and was the 18th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
By country, each count listing its studies:
alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 12 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 314 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 107 across the 43 interventional studies. Of the 40 that completed or were terminated, 30 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 6 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
13 studies in Hypercholesterolemia by Regeneron Pharmaceuticals: none open now, 1 under way, none of them phase 3. Of 12 finished, 10 (83%) have results posted.
Among the 13 studies in Hypercholesterolemia by Regeneron Pharmaceuticals, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is one of 5 that started in 2012, is one of 4 in phase 3, and was the 5th registered.
Regeneron Pharmaceuticals’s Hypercholesterolemia studies by the year they started, since 2010.
2 of the studies testing alirocumab in Hypercholesterolemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477704Regeneron PharmaceuticalsA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia | 2026-12-29 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies testing alirocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Regeneron Pharmaceuticals’s 13 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, double-dummy, active-controlled, parallel-group, multi-national, multi-center study to compare alirocumab (REGN727/SAR236553) versus ezetimibe in participants with primary hypercholesterolemia and moderate, high, or very high CV risk, who are intolerant to statins. An atorvastatin arm is added to determine that the population selected in the study is a truly statin intolerant population by assessing skeletal muscle-related adverse events.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion:
(The inclusion/ exclusion criteria provided above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Atorvastatin 20 mg over-encapsulated tablets orally once daily (QD) for 24 weeks and placebo (for alirocumab) subcutaneous (SC) injection every two weeks (Q2W) for 24 weeks added to stable lipid-modifying therapy (LMT).
Drug: Atorvastatin · Drug: Placebo
Ezetimibe 10 mg over-encapsulated tablets orally QD for 24 weeks and placebo (for alirocumab) SC injection Q2W for 24 weeks added to stable LMT.
Drug: Ezetimibe · Drug: Placebo
Alirocumab 75 mg SC injection Q2W for 24 weeks and placebo (for atorvastatin/ezetimibe) over-encapsulated tablets orally QD for 24 weeks added to stable LMT. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on cardiovascular risk.
Drug: Alirocumab · Drug: Placebo
Atorvastatin over-encapsulated tablets.
Ezetimibe over-encapsulated tablet.
Also known as: Zetia
Alirocumab SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
Also known as: REGN727/SAR236553
Placebo for alirocumab, ezitimibe and atorvastatin.
Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--To-Treat (ITT) Analysis
Calculated LDL-C values were obtained from Friedewald formula. Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Calculated LDL-C at Week 24 - On--Treatment Analysis
Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Calculated LDL--C at Week 12 -- ITT Analysis
Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Calculated LDL-C at Week 12 - On--Treatment Analysis
Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).
Time frame: From Baseline to Week 12
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 -- ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post--baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apo B at Week 24 -- On--Treatment Analysis
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Non--High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 -- ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Non--HDL-C at Week 24 -- On--Treatment Analysis
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Total Cholesterol (Total--C) at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apo B at Week 12 -- ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 12
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis
Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).
Time frame: Up to Week 24
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis
Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first (on-treatment analysis).
Time frame: Up to Week 24
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis
Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).
Time frame: Up to Week 24
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis
Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first (on-treatment analysis).
Time frame: Up to Week 24
Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis
Combined Estimate for Adjusted Mean (Standard Error) at Week 24 from multiple imputation followed by robust regression including all available post-baseline data from Week 4 to Week 24 regardless of status on or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis
Combined Estimate for Adjusted Mean (Standard Error) at Week 24 from multiple imputation followed by robust regression including all available post-baseline data from Week 4 to Week 24 regardless of status on or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Lipoprotein(a) at Week 12 -- ITT Analysis
Combined Estimate for Adjusted Mean (Standard Error) at Week 24 from multiple imputation followed by robust regression including all available post-baseline data from Week 4 to Week 24 regardless of status on or off-treatment.
Time frame: From Baseline to Week 12
Percent Change in HDL-C From Baseline to Week 12 -- ITT Analysis
Least-squares (LS) means and standard errors (SE) taken from MMRM (mixed-effect model with repeated measures) analysis
Time frame: From Baseline to Week 12
Percent Change in Fasting Triglycerides From Baseline to Week 12 -- ITT Analysis
Combined Estimate for Adjusted Mean (Standard Error) at Week 24 from multiple imputation followed by robust regression including all available post-baseline data from Week 4 to Week 24 regardless of status on or off-treatment.
Time frame: From Baseline to Week 12
Percent Change From Baseline in Apo A--1 at Week 12 -- ITT Analysis
Least squares (LS) means and standard errors (SE) taken from MMRM (mixed effect model with repeated measures) analysis.
Time frame: From Baseline to Week 12
Percentage of Participants Who Experienced Skeletal Muscle-related Adverse Event (AE)
Skeletal muscle-related adverse events were a predefined category including myalgia, muscle spasms, muscular weakness, musculoskeletal stiffness and muscle fatigue. Events that developed during treatment emergent adverse events period (the time from the first double-blindstudy treatment \[injection or capsules, whichever came first\] up to the day of the last double-blind injection + 70 days ) are reported.
Time frame: From Baseline up to Week 24
Percent Change From Baseline in Calculated LDL-C at Week 24 Versus Atorvastatin - Raw Data Description - Intent-To-Treat (ITT) Analysis
Time frame: From Baseline up to Week 24
The study was conducted at 67 sites in 8 countries. Overall, 519 participants were screened between 28 September 2012 and 11 August 2013, 158 of whom were screen failures. Screen failures were mainly due to exclusion criteria met. After screening, 361 participants entered into a 4-week single blind placebo run-in period.
| Milestone | Atorvastatin (Statin Rechallenge Arm) | Ezetimibe (Active Comparator) | Alirocumab 75 mg/ up to 150 mg |
|---|---|---|---|
| Started | 63 | 125 | 126 |
| Treated | 63 | 124 | 126 |
| Completed | 42 | 82 | 96 |
| Not completed | 21 | 43 | 30 |
| Withdrew: Randomized but not treated | 0 | 1 | 0 |
| Withdrew: Adverse event | 16 | 31 | 23 |
| Withdrew: Poor compliance to protocol | 2 | 0 | 0 |
| Withdrew: Other | 3 | 11 | 7 |
Calculated LDL-C values were obtained from Friedewald formula. Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).
| percent change | Ezetimibe | Alirocumab 75 mg/ up to 150 mg |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--To-Treat (ITT) Analysis | -14.6 ± 2.2 | -45.0 ± 2.2 |
Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).
| percent change | Ezetimibe | Alirocumab 75 mg/ up to 150 mg |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 24 - On--Treatment Analysis | -17.1 ± 2.0 | -52.2 ± 2.0 |
Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe | Alirocumab 75 mg/ up to 150 mg |
|---|---|---|
| Percent Change From Baseline in Calculated LDL--C at Week 12 -- ITT Analysis | -15.6 ± 2.0 | -47.0 ± 1.9 |
Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first) (on-treatment analysis).
| percent change | Ezetimibe | Alirocumab 75 mg/ up to 150 mg |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 12 - On--Treatment Analysis | -18.0 ± 1.8 | -51.2 ± 1.7 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post--baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe | Alirocumab 75 mg/ up to 150 mg |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 -- ITT Analysis | -11.2 ± 1.7 | -36.3 ± 1.7 |
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first).
| percent change | Ezetimibe | Alirocumab 75 mg/ up to 150 mg |
|---|---|---|
| Percent Change From Baseline in Apo B at Week 24 -- On--Treatment Analysis | -14.4 ± 1.4 | -42.6 ± 1.3 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe | Alirocumab 75 mg/ up to 150 mg |
|---|---|---|
| Percent Change From Baseline in Non--High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 -- ITT Analysis | -14.6 ± 1.7 | -40.2 ± 1.7 |
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first).
| percent change | Ezetimibe | Alirocumab 75 mg/ up to 150 mg |
|---|---|---|
| Percent Change From Baseline in Non--HDL-C at Week 24 -- On--Treatment Analysis | -17.1 ± 1.5 | -46.9 ± 1.4 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe | Alirocumab 75 mg/ up to 150 mg |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol (Total--C) at Week 24 - ITT Analysis | -10.9 ± 1.4 | -31.8 ± 1.4 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe | Alirocumab 75 mg/ up to 150 mg |
|---|---|---|
| Percent Change From Baseline in Apo B at Week 12 -- ITT Analysis | -11.6 ± 1.5 | -36.1 ± 1.5 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe | Alirocumab 75 mg/ up to 150 mg |
|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis | -15.8 ± 1.5 | -41.5 ± 1.5 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe | Alirocumab 75/ up to 150 |
|---|---|---|
| Percent Change From Baseline in Total-C at Week 12 - ITT Analysis | -11.6 ± 1.2 | -32.7 ± 1.2 |
Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).
| percentage of participants | Ezetimibe | Alirocumab 75 mg/ up to 150 mg |
|---|---|---|
| Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis | 4.4 | 41.9 |
Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first (on-treatment analysis).
| percentage of participants | Ezetimibe | Alirocumab 75 mg/ up to 150 mg |
|---|---|---|
| Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis | 5.6 | 51.2 |
Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).
| percentage of participants | Ezetimibe | Alirocumab 75 mg/ up to 150 mg |
|---|---|---|
| Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis | 0.8 | 32.5 |
Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 i.e. up to 21 days after last injection or 3 days after the last capsule, whichever came first (on-treatment analysis).
| percentage of participants | Ezetimibe | Alirocumab 75 mg/ up to 150 mg |
|---|---|---|
| Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis | 0.8 | 39.0 |
Combined Estimate for Adjusted Mean (Standard Error) at Week 24 from multiple imputation followed by robust regression including all available post-baseline data from Week 4 to Week 24 regardless of status on or off-treatment.
| percent change | Ezetimibe | Alirocumab 75 mg/ up to 150 mg |
|---|---|---|
| Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis | -7.3 ± 2.5 | -25.9 ± 2.4 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe | Alirocumab 75 mg/ up to 150 mg |
|---|---|---|
| Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis | 6.8 ± 1.7 | 7.7 ± 1.7 |
Combined Estimate for Adjusted Mean (Standard Error) at Week 24 from multiple imputation followed by robust regression including all available post-baseline data from Week 4 to Week 24 regardless of status on or off-treatment.
| percent change | Ezetimibe | Alirocumab 75 mg/ up to 150 mg |
|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis | -3.6 ± 2.8 | -9.3 ± 2.7 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Ezetimibe | Alirocumab 75 mg/ up to 150 mg |
|---|---|---|
| Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis | 2.9 ± 1.2 | 4.8 ± 1.2 |
Combined Estimate for Adjusted Mean (Standard Error) at Week 24 from multiple imputation followed by robust regression including all available post-baseline data from Week 4 to Week 24 regardless of status on or off-treatment.
| percent change | Ezetimibe | Alirocumab 75 mg/ up to 150 mg |
|---|---|---|
| Percent Change From Baseline in Lipoprotein(a) at Week 12 -- ITT Analysis | -4.5 ± 2.3 | -21.7 ± 2.2 |
Least-squares (LS) means and standard errors (SE) taken from MMRM (mixed-effect model with repeated measures) analysis
| percent change | Ezetimibe | Alirocumab 75 mg/ up to 150 mg |
|---|---|---|
| Percent Change in HDL-C From Baseline to Week 12 -- ITT Analysis | 7.6 ± 1.2 | 9.0 ± 1.2 |
Combined Estimate for Adjusted Mean (Standard Error) at Week 24 from multiple imputation followed by robust regression including all available post-baseline data from Week 4 to Week 24 regardless of status on or off-treatment.
| percent change | Ezetimibe | Alirocumab 75 mg/ up to 150 mg |
|---|---|---|
| Percent Change in Fasting Triglycerides From Baseline to Week 12 -- ITT Analysis | -9.4 ± 2.6 | -8.0 ± 2.5 |
Least squares (LS) means and standard errors (SE) taken from MMRM (mixed effect model with repeated measures) analysis.
| percent change | Ezetimibe | Alirocumab 75 mg/ up to 150 mg |
|---|---|---|
| Percent Change From Baseline in Apo A--1 at Week 12 -- ITT Analysis | 3.9 ± 1.0 | 5.5 ± 1.0 |
Skeletal muscle-related adverse events were a predefined category including myalgia, muscle spasms, muscular weakness, musculoskeletal stiffness and muscle fatigue. Events that developed during treatment emergent adverse events period (the time from the first double-blindstudy treatment \[injection or capsules, whichever came first\] up to the day of the last double-blind injection + 70 days ) are reported.
| Percentage of Participants | Atorvastatin (Statin Rechallenge Arm) | Ezetimibe (Active Comparator) | Alirocumab 75 mg/ up to 150 mg |
|---|---|---|---|
| Any skeletal muscle-related AE | 46.0 | 41.1 | 32.5 |
| Leading to treatment discontinuation | 22.2 | 20.2 | 15.9 |
| percent change | Atorvastatin (Statin Rechallenge Arm) | Ezetimibe (Active Comparator) | Alirocumab 75 mg/ up to 150 mg |
|---|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 24 Versus Atorvastatin - Raw Data Description - Intent-To-Treat (ITT) Analysis | -31.9 ± 25.1 | -15.2 ± 22.4 | -47.3 ± 22.7 |
Collected over From Baseline up to the Last Double-Blind Injection Date + 70 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Atorvastatin | — | 7/63 (11.1%) | 35/63 (55.6%) |
| Ezetimibe | — | 10/124 (8.1%) | 63/124 (50.8%) |
| Alirocumab 75 mg/ up to 150 mg | — | 12/126 (9.5%) | 57/126 (45.2%) |
| Event | Atorvastatin | Ezetimibe | Alirocumab 75 mg/ up to 150 mg |
|---|---|---|---|
| Non-Cardiac chest painGeneral disorders | 1/63 | 4/124 | 0/126 |
| Angina unstableCardiac disorders | 1/63 | 0/124 | 1/126 |
| NauseaGastrointestinal disorders | 1/63 | 0/124 | 0/126 |
| Small intestinal obstructionGastrointestinal disorders | 1/63 | 0/124 | 0/126 |
| VomitingGastrointestinal disorders | 1/63 | 0/124 | 0/126 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/63 | 0/124 | 0/126 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/63 | 0/124 | 0/126 |
| Ovarian epithelial cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/63 | 0/124 | 0/126 |
| Transient ischaemic attackNervous system disorders | 1/63 | 0/124 | 0/126 |
| Aortic aneurysmVascular disorders | 1/63 | 0/124 | 0/126 |
| Event | Atorvastatin | Ezetimibe | Alirocumab 75 mg/ up to 150 mg |
|---|---|---|---|
| MyalgiaMusculoskeletal and connective tissue disorders | 17/63 | 29/124 | 31/126 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 7/63 | 9/124 | 5/126 |
| NasopharyngitisInfections and infestations | 2/63 | 10/124 | 8/126 |
| FatigueGeneral disorders | 5/63 | 4/124 | 6/126 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/63 | 9/124 | 6/126 |
| Back painMusculoskeletal and connective tissue disorders | 5/63 | 7/124 | 5/126 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 4/63 | 2/124 | 1/126 |
| HeadacheNervous system disorders | 4/63 | 6/124 | 6/126 |
| ParaesthesiaNervous system disorders | 4/63 | 0/124 | 4/126 |
| Upper respiratory tract infectionInfections and infestations | 2/63 | 5/124 | 7/126 |
| Age, Continuous(years) | Atorvastatin (Statin Rechallenge Arm) | Ezetimibe (Active Comparator) | Alirocumab 75 mg/ up to 150 mg | Total |
|---|---|---|---|---|
| Mean | 63.4 ± 9.5 | 62.8 ± 10.1 | 64.1 ± 9.0 | 63.4 ± 9.5 |
| Sex: Female, Male(Participants) | Atorvastatin (Statin Rechallenge Arm) | Ezetimibe (Active Comparator) | Alirocumab 75 mg/ up to 150 mg | Total |
|---|---|---|---|---|
| Female | 28 | 58 | 56 | 142 |
| Male | 35 | 67 | 70 | 172 |
| Low Density Lipoprotein Cholesterol (LDL-C) in mg/dL(mg/dL) | Atorvastatin (Statin Rechallenge Arm) | Ezetimibe (Active Comparator) | Alirocumab 75 mg/ up to 150 mg | Total |
|---|---|---|---|---|
| Mean | 187.3 ± 59.5 | 193.5 ± 70.9 | 191.1 ± 72.7 | 191.3 ± 69.3 |
| LDL-C in mmol/L(mmol/L) | Atorvastatin (Statin Rechallenge Arm) | Ezetimibe (Active Comparator) | Alirocumab 75 mg/ up to 150 mg | Total |
|---|---|---|---|---|
| Mean | 4.85 ± 1.54 | 5.011 ± 1.837 | 4.951 ± 1.883 | 4.954 ± 1.796 |
Ran from Sep 2012 to primary completion in May 2014, 20 months.
Results were first posted in Aug 2015, 1 year 2 months after primary completion. A results delay was requested in Jan 2015.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 20 months is above that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alirocumab